肿瘤标志物在左右半大肠腺癌中的研究价值及意义

Abstract
Figure/Table
References (21)
Related Citation (0)

Download: PDF (566 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the value and significance of CEA, CA125, CA724 and CA199 in the diagnosis and judgment of left and right sided colorectal adenocarcinomas. Methods A total of 162 patients with colorectal adenocarcinomas were diagnosed by pathology from July 2015 to July 2016 in Renmin Hospital of Wuhan University were retrospectively analyzed, including 97 cases of left colorectal adenocarcinomas and 65 cases of right colorectal adenocarcinomas. The serum tumor markers and clinical and pathological parameters of the patients were collected and the differences between left and right colorectal adenocarcinomas were analyzed. Results The positive rate of CEA, CA125, CA724 and CA199 in the left colorectal cancer patients were 38.1%, 25.8%, 62.9% and 30.9%, and the positive rate of four serum markers was 59.8%. The positive rate of CEA, CA125, CA724 and CA199 in 53 patients with right colorectal cancer were 53.8%, 23.0%, 46.2% and 40.0%, respectively, and the positive rate of the combination of four markers was 64.6%. The positive rate of CA125 in the left half of the results of neural invasion of colorectal adenocarcinoma, CA199 in the right half of the results of neural colorectal adenocarcinoma, the difference was statistically significant, CA199 in the left and right semi-colorectal adenocarcinoma vascular invasion was different with those without neural invasion (P < 0.05). Conclusion Tumor markers CEA, CA125, CA724, CA199 in the left and right colorectal adenocarcinoma in the presence of differences, combined detection can improve the positive rate. CA125 and CA199 on the left and right colorectal adenocarcinoma nerve involvement have a guiding significance, CA199 on the left and right colorectal adenocarcinoma vascular invasion has a guiding significance.

Key words： Colorectal adenocarcinoma Serum tumor markers CEA CA125 CA724 CA199

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Wenjun GE Wei WU Long

Cite this article:

ZHANG Wenjun GE Wei WU Long. Comparative study of tumor markers and its significance in left and right sided colorectal adenocarcinoma[J]. 中国医药导报, 2017, 14(34): 4-7,12.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I34/4

[1] Song X，Hong Z，Qian P，et al. Significance of inflammation-based indices in the prognosis of patients with non-metastatic colorectal cancer [J]. Oncotarget，2017，8（28）：45 178-45 189.
[2] Siegel RL，Miller KD，Jemal A. Cancer statistics，2016 [J]. CA Cancer J Clin，2016，66（1）：7-30.
[3] Quirke P，Risio M，Lambert R，et al. Quality assurance in pathology in colorectal cancer screening and diagnosis——European recommendations [J]. Virchows Archiv，2011，458（1）：1-19.
[4] Li Q，Dai W，Li Y，et al. Nomograms for predicting the prognostic value of serological tumor biomarkers in colorectal cancer patients after radical resection [J]. Sci Rep，2017，7：46 345.
[5] Duffy MJ，Lamerz R，Haglund C，et al. Tumor markers in colorectal cancer，gastric cancer and gastrointestinal stromal cancers：European group on tumor markers 2014 guidelines update [J]. Int J Cancer，2014，134（11）：2513-2522.
[6] Primrose JN，Perera R，Gray A，et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer：the FACS randomized clinical trial [J]. JAMA，2014，311（3）：263-270.
[7] Thomas DS，Fourkala EO，Apostolidou S，et al. Evaluation of serum CEA，CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples [J]. Br J Cancer，2015，113（2）：268-274.
[8] Pavlopoulou A，Scorilas A. A Comprehensive Phylogenetic and Structural Analysis of the Carcinoembryonic Antigen （CEA） Gene Family [J]. Genome Biol Evol，2014，6（6）：1314-1326.
[9] Lee JH，Lee SW. The Roles of Carcinoembryonic Antigen in Liver Metastasis and Therapeutic Approaches [J]. Gastroenterol Res Pract，2017，2017（13）：7 521 987.
[10] Duffy MJ，Lamerz R，Haglund C，et al. Tumor markers in colorectal cancer，gastric cancer and gastrointestinal stromal cancers： European group on tumor markers 2014 guidelines update[J]. Int J Cancer，2014，134（11）：2513-2522.
[11] Pakdel A，Malekzadeh M，Naghibalhossaini F. The association between preoperative serum CEA concentrations and synchronous liver metastasis in colorectal cancer patients [J]. Cancer Biomark，2016，16（2）：245-252.
[12] Chen XZ，Zhang WK，Yang K，et al. Correlation between serum CA724 and gastric cancer：multiple analyses based on Chinese population [J]. Mol Biol Rep，2012，39（9）：9031-9039.
[13] Zhao S，Mei Y，Wang Y，et al. Levels of CEA，CA153，CA199，CA724 and AFP in nipple discharge of breast cancer patients [J]. Int J Clin Exp Med，2015，8（11）：20837-20844.
[14] Zhu ZM，Chen Z，Chen CL，et al. Opposite variation tendencies of serum CA724 levels in patients with colon and rectal carcinoma [J]. Mol Clin Oncol，2014，2（1）：139-145.
[15] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012. [J]. Ca A Cancer Journal for Clinicians，2015， 65（2）：87-108.
[16] 陈蕾，姜北海，邸佳柏.CA199在判断CEA正常的中晚期结直肠癌患者预后中的价值[J].临床研究与应用，2015， 42（15）：743-750.
[17] Wang J，Wang X，Yu F，Chen J，et al. Combined detection of preoperative serum CEA，CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients [J]. Int J Clin Exp Pathol，2015，8（11）：14 853-14 863.
[18] Verdaguer H，Saurí T，Macarulla T. Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment [J]. J Gastrointest Oncol，2017，8（3）：405-417.
[19] Grady WM，Pritchard CC. Molecular alterations and biomarkers in colorectal cancer [J]. Toxicologic Pathology，2014， 42（1）：124.
[20] Gao XH，Yu GY，Gong HF，et al. Differences of protein expression profiles，KRAS and BRAF mutation，and prognosis in right-sided colon，left-sided colon and rectal cancer [J]. Sci Rep，2017，7（1）：7882.
[21] Kara O，Duman BB，Kara B，et al. Analysis of PTEN，VEGF，HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy [J]. Asian Pac J Cancer Prev，2012，13（12）：6397-6401.